Trials / Completed
CompletedNCT00437840
A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809
A Placebo-controlled, Single-blind, Randomised, Human Volunteer Study Investigating the Tolerability and Pharmacokinetics of Escalating Single Oral Doses of GSK598809 in Smokers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
GSK598809 is being developed to facilitate overcoming an addiction to nicotine and to help people stop smoking. This study will investigate if GSK598809 is safe and tolerated in people who smoke and will also look at blood levels of GSK598809 and nicotine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK598809 | GSK598809 capsules will be available in dose strength of 5 and 25 mg. Subjects will receive single oral dose of GSK598809 n order to achieve the required dose. |
| DRUG | Placebo | Subjects will receive single oral dose of matching placebo tablet to GSK598809. |
Timeline
- Start date
- 2007-03-20
- Primary completion
- 2007-06-20
- Completion
- 2007-06-20
- First posted
- 2007-02-21
- Last updated
- 2017-08-07
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00437840. Inclusion in this directory is not an endorsement.